ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pain"

  • Abstract Number: 0311 • ACR Convergence 2025

    Time series analysis of continuous accelerometry data to determine the impact of symptomatic multiple joint osteoarthritis (MJOA) in the naturally occurring canine model

    Elizabeth Kawecki-Wright1, Liubov Arbeeva2, Christina Stevens1, Masataka Enomoto1, Amanda Nelson3, Margaret Gruen1 and Duncan Lascelles1, 1North Carolina State University, RALEIGH, NC, 2University of North Carolina, Chapel Hill, Carrboro, NC, 3University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Pet dogs are a promising translational model for naturally occurring multiple joint osteoarthritis (MJOA). We characterized the impact of symptomatic (sx) MJOA, over the…
  • Abstract Number: 2353 • ACR Convergence 2025

    Efficacy of Vunakizumab in Reducing Pain in Ankylosing Spondylitis: A Post-Hoc Analysis of a Phase 2/3 Clinical Trial

    Jian Xu, Yifan Yang, Shuang Liu, Ru Bai, Shu Li, Guofang Zhang, Xiangyu Wang, Xinyu Xu, Mai Zheng and Daying Feng, The First Affiliated Hospital of Kunming Medical University, Kunming, China (People's Republic)

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints, resulting in significant pain, stiffness, and functional impairment.…
  • Abstract Number: 2080 • ACR Convergence 2025

    Foot laterality does not modify outcome of knee and/or hip osteoarthritis

    Simon Fondin1, Armand Eyraud1, Estelle Nkonda1, Anne-Christine Rat2, Bruno Fautrel3, SELLAM JEREMIE4, Christian Roux5, Jacques Pouchot6, Joel Coste7, Francis Guillemin8 and Alain SARAUX9, 1Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, 2Caen University hospital, UMR 1075 Caen normandy university, Caen, France, 3Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS 1136-5, PARIS, France, Paris, France, 4Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, 184, rue du Faubourg Saint-Antoine, 75012, Paris, France., Paris, France, 5CHU Nice, Nice, France, 6AP-HP, Rueil Malmaison, France, 7APHP, Paris, France, 8CHU Nancy, Nancy, France, 9CHU Brest, Brest, France

    Background/Purpose: Hip and knee osteoarthritis (OA) are among the leading causes of global disability. Global OA is more prevalent on the right side. This discordance…
  • Abstract Number: 1636 • ACR Convergence 2025

    The Impact of Arthritis on Self-Management Activities of West Virginia Adults with Type 2 Diabetes During the COVID-19 Pandemic

    Dina Maruca1, Teresa Brady2, Gerald Hobbs, Jr.1 and Ranjita Misra1, 1West Virginia University, Morgantown, WV, 2Clarity Consulting and Communications, Atlanta, GA

    Background/Purpose: One-third of adults with Type 2 diabetes (T2D) also have arthritis. West Virginia (WV), the 3rd most rural US state, has the highest prevalence…
  • Abstract Number: 1240 • ACR Convergence 2025

    Serum Olink Proteomics Identifies Novel Mediators of Pain in Lupus Nephritis Patients Without Extrarenal Clinical Activity

    Sarah Keegan1, Philip Carlucci2, Peter Izmirly3, Erin Carter4, Sanchit Sanyal5, Brooke Cohen6, Jasmine Shwetar7, Katie Preisinger8, Devyn Zaminski6, Kristina Deonaraine6, Mala Masson9, Andrea Fava10, Judith James11, Rufei Lu11, Wade DeJager12, Chaim Putterman13, Michael Belmont14, Richard Furie15, Maria Dall'Era16, Diane Kamen17, Kenneth Kalunian18, Jennifer Anolik19, David Wofsy20, Jennifer Barnas21, Nir Hacohen22, Robert Clancy23, Joel Guthridge11, Brad Rovin24, Michelle Petri25, Jill Buyon3 and Kelly Ruggles26, 1NYU Langone, New York, 2New York University School of Medicine, New York, NY, 3NYU Grossman School of Medicine, New York, NY, 4New York University Grossman School of Medicine, New York, NY, 5Johns Hopkins University School of Medicine, Baltimore, MD, 6NYU Langone, NYC, 7New York University School of Medicine, Department of Medicine, New York, 8NYU Langone, NYU Langone, 9NYU Langone Medical Center- Division of Rheumatology, New York, NY, 10Johns Hopkins University, Baltimore, MD, 11Oklahoma Medical Research Foundation, Oklahoma City, OK, 12Oklahoma Medical Research Foundation, Oklahoma City, 13Albert Einstein College of Medicine, Safed, Israel, 14NYU Langone Health, New York, NY, 15Division of Rheumatology, Northwell Health, Great Neck, NY, 16Division of Rheumatology, University of California, San Francisco, CA, 17Medical University of South Carolina, Johns Island, SC, 18UC San Diego, La Jolla, CA, 19University of Rochester Medical Center, Rochester, NY, 20University of California San Francisco, SF, CA, 21University of Rochester, Rochester, NY, 22Broad Institute of MIT Harvard, Cambridge, MA, 23Columbia University, New York, NY, 24The Ohio State University, Columbus, OH, 25Johns Hopkins University School of Medicine, Timonium, MD, 26NYU Grossman School of Medicine, Brooklyn, NY

    Background/Purpose: For patients with lupus nephritis, active disease can be solely renal or include a range of extrarenal signs, such as arthritis or serositis, that…
  • Abstract Number: 1223 • ACR Convergence 2025

    Pain and Fibromyalgia Across Autoimmune and Inflammatory Diseases in the AMP AIM Cohort

    Alexis Ogdie1, Astrid Rasmussen2, Dana Orange3, Michelle Petri4, Caroline Shiboski5, Rebecca Haberman6, Mala Masson7, Daniel Goldman4, Peter Izmirly8, Brooke Cohen9, Jennifer Seifert10, Jennifer Anolik11, Wade DeJager12, Alan Baer13, Jill Buyon14 and Yvonne Lee15, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3The Rockefeller University, New York, NY, 4Johns Hopkins University School of Medicine, Timonium, MD, 5University of California San Francisco, San Francisco, CA, 6NYU Langone Health, New York, NY, 7NYU Langone Medical Center- Division of Rheumatology, New York, NY, 8New York University Grossman School of Medicine, New York, NY, 9Yale Physician Associate Program, New Haven, CT, 10University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, 11University of Rochester Medical Center, Rochester, NY, 12Oklahoma Medical Research Foundation, Oklahoma City, 13Johns Hopkins University School of Medicine, Baltimore, MD, 14NYU Grossman School of Medicine, New York, NY, 15Northwestern University, Chicago, IL

    Background/Purpose: The Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) network seeks to understand the cellular and molecular interactions that lead to inflammation and…
  • Abstract Number: 0530 • ACR Convergence 2025

    Evaluating ChatGPT’s Performance in Diagnosing Low Back Pain: A Comparison with Clinicians and Impact of Prompted Specialties

    Annika Nack1, Xabier Michelena Vegas2, Pol Maymó-Paituvi3, Cristina Calomarde-Gómez4, david lobo5, Asier García-Alija6, Raquel Ugena-García4, Maria Aparicio1, Paola Vidal Montal7 and Diego Benavent8, 1Hospital Germans Trias i Pujol, Barcelona, Spain, 2Hospital Universitari Vall Hebron, Barcelona, Spain, 3Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, 4Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 5Doctor Josep Trueta University Hospital, Girona, Catalonia, Spain, 6Sant Pau Hospital, Barcelona, Catalonia, Spain, 7Bellvitge University Hospital, Barcelona, Spain, 8Hospital Universitari de Bellvitge, Madrid, Spain

    Background/Purpose: Low back pain (LBP) is a multifactorial condition managed by various specialists. AI chatbots like ChatGPT may help clinicians identify probable diagnoses. Given that…
  • Abstract Number: 0308 • ACR Convergence 2025

    Artificial Intelligence Assisted Extraction of Patient-Reported Pain Outcomes in Osteoarthritis Using Prompt Engineering of Large Language Models

    Jainesh Doshi1, Stephen Batter1, Yiyuan Wu2, Alice Santilli1, Sandhya Kannayiram3, Susan Goodman4 and Bella Mehta5, 1Hospital for Special Surgery, New York, 2Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, 4Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 5Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ

    Background/Purpose: Unstructured data in physician notes can be incredibly valuable, especially for understanding patient-reported outcomes (PROs), which are often mentioned in these notes.In this study,…
  • Abstract Number: 2342 • ACR Convergence 2025

    Real-World Effectiveness and Satisfaction in Biologic-Naïve Patients With Psoriatic Arthritis and Limited Joint Involvement Treated With Risankizumab in the United States and Europe

    Andrew Ostor1, Jessica A. Walsh2, Christopher Saffore3, Xiaolan Ye4, Manish Patel5, Ana Biljan6, Jamie Vora7, Isabel Truman8, Molly Edwards8, Gary Milligan8 and William Tillett9, 1Australian National University, Canberra, Australia, 2Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, 3AbbVie Inc., waukegan, IL, 4AbbVie Inc., Mettawa, IL, 5AbbVie Inc., North Chicago, IL, 6AbbVie Inc., Buffalo Grove, IL, 7AbbVie Inc., Palatine, IL, 8Adelphi Real World, Bollington, United Kingdom, 9Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom

    Background/Purpose: This study evaluated real-world effectiveness and patient- and physician-satisfaction with risankizumab (RZB) for biologic-naïve PsA patients with limited joint involvement or oligoarthritis.Methods: Data were…
  • Abstract Number: 2065 • ACR Convergence 2025

    Pain in Idiopathic Inflammatory Myopathies: A Global Study of Patient Experience

    Lekshmi Minikumari Rahulan1, Shounak Ghosh2, Manali Sarkar3, Didem Saygin4, Karin Lodin5, Rima Shrestha6, Tulika Chatterjee7, Jessica Day8, Samuel Shinjo9, Sreoshy Saha10, Lorenzo Cavagna11, Masataka Kuwana12, Vikas Agarwal13 and Latika Gupta14, 1Sanjay Gandhi Postgraduate Institute of Medical sciences Lucknow, Lucknow, Uttar Pradesh, India, 2Department of Rheumatology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK, Wolverhampton, United Kingdom, 3Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, 4Rush University Medical Center, Chicago, IL, 5Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 6Department of Internal Medicine, University of Illinois College of Medicine Peoria, Illinois, United States, Department of Research Services, University of Illinois College of Medicine Peoria, Illinois, United States, Illinois, 7Department of Internal Medicine, University of Illinois College of Medicine Peoria, Illinois, United States, Illinois, 8Walter and Eliza Hall Institute, Melbourne, Victoria, Australia, 9Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, 10Mymensingh Medical College, Mymensingh, Bangladesh, Mymensingh, Bangladesh, 11Associate Professor in Rheumatology (Internal Medicine and Thepaeutics),University of Pavia, Pavia, Lombardy, Italy, Physician in Chief of Myositis Outpatients Clinic,Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia,Italy, Lombardia, Italy, 12Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 13Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 14School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom

    Background/Purpose: Pain remains a significant yet understudied aspect of idiopathic inflammatory myopathies (IIMs), considerably reducing quality of life despite advancements in immunomodulatory therapies. Information obtained…
  • Abstract Number: 1487 • ACR Convergence 2025

    Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement

    Jennifer Rogers1, Amanda Eudy2, Connor Drake3, Tamara Somers4, David Pisetsky5, Christie Clipper6, Ralph Snyderman7, Anna Batsakes6, Leigh Saner6, Dana Burshell3, Mithu Maheswaranathan4, Lisa Criscione-Schreiber4, Rebecca Sadun8, Nathaniel Harris5, Kai Sun8, Kelsey Dunn6, Jenny Herndon6, Vonne Jacobs6 and Megan Clowse9, 1Duke, Durham, NC, 2Duke University, Raleigh, NC, 3Duke University School of Medicine, Durham, 4Duke University School of Medicine, Durham, NC, 5Duke University Medical Center, Durham, NC, 6Duke University, Durham, 7Duke Center for Personalized Health Care, Durham, NC, 8Duke University, Durham, NC, 9Duke University, Chapel Hill, NC

    Background/Purpose: To improve quality of life (QoL) in individuals with SLE, we developed the Whole Health Empowerment for Endotypes of Lupus (WHEEL) program—a 4-month, biweekly,…
  • Abstract Number: 1239 • ACR Convergence 2025

    JAK inhibition appears to alter clinical and neurobiological markers of nociplastic pain in rheumatoid arthritis: a 7T MRI Brain study

    Kristian Stefanov1, Andrew McGucken1, Maxine Arnott1, Tyrone Lau1, Norah Aldehmi1, Vinod Kumar2, Neil McKay3, James Dale4, Lindsay Robertson5, James Brock1, Flavia Sunzini6 and Neil Basu7, 1University of Glasgow, Glasgow, United Kingdom, 2NHS Tayside, Dundee, United Kingdom, 3NHS Lothian, Edinburgh, United Kingdom, 4NHS Lanarkshire, Wishaw, United Kingdom, 5NHS Grampian, Aberdeen, United Kingdom, 6Glasgow University, Glasgow, United Kingdom, 7Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Pain remains a prevalent and highly impactful issue for people with rheumatoid arthritis (RA). Among modern day targeted therapies, the janus kinase (JAK) inhibitors…
  • Abstract Number: 1196 • ACR Convergence 2025

    Prevalence of and Factors Associated with Chronic Opioid Use among Individuals with Inflammatory Myopathies

    Anuya Natu1, Haley Zimmerman2, Kristin Wipfler3, Kaleb Michaud4, Yvonne Lee5 and Didem Saygin2, 1John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, 2Rush University Medical Center, Chicago, IL, 3FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE, 5Northwestern University, Chicago, IL

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) can be associated with significant pain and functional impairment. While the use of opioids has been documented in other inflammatory…
  • Abstract Number: 0503 • ACR Convergence 2025

    Impact of Olokizumab on Pain in Rheumatoid Arthritis: a Meta-analysis

    Andrey E. Karateev1, Sofia Kuzkina2, Alina Egorova3 and Elena Y. Polishchuk1, 1V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 2R-Pharm, Moscow, Russia, 3R-Pharm JSC, Moscow, Russia

    Background/Purpose: Pain is one of the most debilitating symptoms of rheumatoid arthritis (RA) and a major contributor to reduced quality of life. Persistent joint pain…
  • Abstract Number: 0292 • ACR Convergence 2025

    Patterns and Predictors of Longitudinal Trajectories of Pain in Individuals with Inflammatory Myopathies

    Haley Zimmerman1, Ethan Ritz2, Kristin Wipfler3, Kaleb Michaud4 and Didem Saygin1, 1Rush University Medical Center, Chicago, IL, 2Rush Research Informatics Core, Rush University Medical Center, Chicago, IL, 3FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) have historically been considered a disease of painless weakness. However, recent studies indicate that most patients with IIM experience pain…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology